Predicting Risk for Richter’s Transformation

A panel of chronic lymphocytic leukemia experts including Dr. Farrukh Awan, Dr. Philip Thompson from MD Anderson Cancer Center and Dr. Nicole Lamanna from Columbia University Medical Center discuss Richter’s transformation in chronic lymphocytic leukemia, genetic markers that increase a patient’s disease risk and therapies in development. Watch now to hear their expert perspectives.

This program is sponsored by AbbVie Inc., Genentech, Inc. and Adaptive Biotechnologies. These organizations have no editorial control. It is produced by Patient Power, and Patient Power is solely responsible for program content.

Key Takeaways

  • Richter’s transformation is a transformation of B-cell chronic lymphocytic leukemia (CLL) into a fast-growing diffuse large B-cell lymphoma, a variety of non-Hodgkin lymphoma.
  • People with high-risk disease features who have chemotherapy may be at even higher risk for Richter’s.
This article was originally published February 7, 2020 and most recently updated May 21, 2021.
© 2024 HealthCentral LLC. All rights reserved.

More on Chronic Lymphocytic Leukemia